Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7

Related Articles by Review for PubMed (Select 21351148)

1.

Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5.

Frost M, Andersen T, Gossiel F, Hansen S, Bollerslev J, van Hul W, Eastell R, Kassem M, Brixen K.

J Bone Miner Res. 2011 Aug;26(8):1721-8. doi: 10.1002/jbmr.376.

PMID:
21351148
2.
3.

[Serum sclerostin levels and metabolic bone diseases].

Yamauchi M, Sugimoto T.

Clin Calcium. 2013 Jun;23(6):877-83. doi: CliCa1306877883. Review. Japanese.

PMID:
23719501
4.

Clinical review: Genome-wide association studies of skeletal phenotypes: what we have learned and where we are headed.

Hsu YH, Kiel DP.

J Clin Endocrinol Metab. 2012 Oct;97(10):E1958-77. doi: 10.1210/jc.2012-1890. Epub 2012 Sep 10. Review.

5.

Sclerostin monoclonal antibodies on bone metabolism and fracture healing.

Gamie Z, Korres N, Leonidou A, Gray AC, Tsiridis E.

Expert Opin Investig Drugs. 2012 Oct;21(10):1523-34. Epub 2012 Jul 31. Review.

PMID:
22849579
6.

The two faces of serotonin in bone biology.

Ducy P, Karsenty G.

J Cell Biol. 2010 Oct 4;191(1):7-13. doi: 10.1083/jcb.201006123. Review.

7.

Regulation of bone mass by serotonin: molecular biology and therapeutic implications.

Karsenty G, Yadav VK.

Annu Rev Med. 2011;62:323-31. doi: 10.1146/annurev-med-090710-133426. Review.

PMID:
21073335
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk